May 10th, 2022 5:00-6:00pm ET
The overall goal of this project is to help identify critical gaps in standard biomarker testing and help improve understanding of targeted based therapies for patients with non-small cell lung cancer (NSCLC). Furthermore, this educational series would allow oncology team members to become more familiar with the targeted based approaches for less common mutations and make treatment decisions to promote better care for patients.
Biomarker based testing and precision medicine based approaches have become a standard to guide treatment decisions for metastatic non-small cell lung cancer (NSCLC) and are crucial even for early stage/resected patients. There are several barriers that prevent optimal testing for patients, but the discovery of novel molecular targets and subsequent development of targeted therapies make it critical to find ways to overcome these barriers. As treatment progresses, there is a potential to develop resistance mechanisms to commonly used targeted therapies; these new targets are identified by the integration of precision medicine.
It is imperative for all members of the lung cancer treatment team (oncologists, pathologists, pharmacists, nurse practitioners, nurses, and physicians’ assistants) and even patients to understand this data and recognize the complexity of managing these patients using a precision medicine based approach in both first line and subsequent line therapies.
This webinar will be a roundtable discussion with a pharmacist, oncologist, and patient to identify clinical pearls and best practices for ALK-rearranged NSCLC. We will focus on:
Overcoming barriers and differences of biomarker testing
Reviewing ALK-rearrangements and first line therapy in mNSCLC
Perspective on re-biopsy at progression and subsequent treatment based on resistance
Management of adherence and toxicity for patients prescribed ALK-directed therapy